Hiberix (Haemophilus Type B Conjugate Vaccine (Tetanus Toxoid Conjugate))

Hiberix is indicated for the prevention of infections caused by Haemophilus influenzae type b (Hib).

• Primary immunization series in infants and young children.
• Booster doses as recommended by national immunization schedules.
• Use in children older than 12 months who have not completed the primary series.
• Administration to adults at increased risk of Hib disease, such as those with certain immunodeficiencies.
• Co‑administration with other routine childhood vaccines when appropriate.
• May be given to travelers to regions where Hib disease remains endemic.

• Hiberix works by coupling the capsular polysaccharide polyribosylribitol phosphate (PRP) of Haemophilus influenzae type b to a carrier protein, tetanus toxoid. This conjugate enables the antigen to be processed by antigen‑presenting cells and presented to T‑helper cells, which in turn stimulate B‑cell production of high‑affinity anti‑PRP antibodies. The resulting humoral response provides active immunity that prevents invasive Hib disease. Memory B cells generated by the vaccine contribute to long‑term protection.

Local and systemic reactions may occur after injection of Hiberix; most are mild and resolve without medical intervention. These reactions are typically self‑limited and do not require specific treatment. Healthcare providers monitor patients after vaccination to ensure any adverse event is promptly addressed.

Common

• Pain, redness, or swelling at the injection site.
• Low‑grade fever (≤38.5 °C).
• Irritability or fussiness in infants.
• Mild headache or fatigue.
• Mild muscle aches.
• Temporary loss of appetite.

Serious

• Severe allergic reaction (anaphylaxis) with difficulty breathing, hives, or swelling of the face.
• High fever (≥39 °C) persisting more than 24 hours.
• Seizures associated with fever.
• Persistent crying or inconsolable distress.
• Guillain‑Barré syndrome (very rare).
• Encephalopathy (very rare).

Before administering Hiberix, clinicians should evaluate the patient’s medical history and current health status to minimize risk.

• Confirm no severe allergic reaction to any component of the vaccine, especially tetanus toxoid.
• Defer vaccination in individuals with acute moderate or severe illness until recovery.
• Use caution in patients with a known immunodeficiency, as response may be reduced.
• Discuss with pregnant or breastfeeding women; safety data are limited, and vaccination should follow professional guidance.
• Observe the patient for at least 15 minutes after injection for immediate hypersensitivity.
• Record any previous Hib vaccination to avoid unnecessary repeat dosing.

Hiberix does not have many documented drug‑drug interactions, but certain circumstances warrant attention.

Avoid

• Concurrent administration of other live vaccines at the same anatomical site; separate sites or timing is recommended.
• Use with immunosuppressive therapies that may markedly diminish the vaccine’s immunogenicity.
• Simultaneous intramuscular injection with other vaccines containing adjuvants that may increase reactogenicity.

Use with caution

• Simultaneous receipt of other inactivated vaccines; monitor for increased local reactions.
• Administration in patients receiving high‑dose steroids; assess antibody response.
• Co‑administration with antipyretics may mask low‑grade fever, though it does not affect efficacy.
• Administration in patients on anticoagulant therapy; apply pressure to injection site to reduce bruising.